The new drug is used to treat cases of HER2-positive breast cancer, a type of breast cancer that is diagnosed by examining the tumor-positive tide of a protein called HER2. The presence of this protein promotes cancer 3 cell development. It is also the first targeted treatment for breast cancer with low concentration levels of HER2 protein known as HER2Low.
Scientific studies suggest that the drug may reclassify widespread breast cancer types in terms of treatment, change doctors’ trends to identify HER2 low/HER2 + patients and treat them for breast cancer as this segment represents 60% of prevalent breast cancer patients.
Dr. Ahmed Sayyam, Head of the Medical Sector of AstraZeneca Egypt, noted that the drug Enhertu developed by AstraZeneca is one of the latest properties to attack cancer cells carrying the protein HER2. He explained that the drug works by binding to the HER2 protein on the surface of the cancer tumor, before releasing a dose of chemotherapy directly into the cancer cells, destroying it from the inside out.
Based on validated research, the medication offers patients with breast cancer new possibilities for overcoming the challenges brought on by their illness.
According to Dr. Ibtisam Saaddin, an oncology professor at the University of Cairo, breast cancer is the primary cause of death for cancer patients and accounts for over 33% of cancer-related deaths in Egypt.
In addition, she mentioned that the causes of breast cancer remain unknown. However, there are many factors that may contribute to this disease, including age and family history of the disease, genetic and hormonal mutations, etc., Therefore, early detection of prevention should be carried out, especially when women reach the age of 40. If there is a family history of cancer, screening begins 5 years before the youngest infected family members, or at the age of 30 at most.
Dr. Mohsen Mukhtar, Professor of Oncology, University of Cairo, pointed out: “If it is observed that there is a painful or painless mass in the breast area or other symptoms such as redness or change in the color or texture of the human person, the master should go to an oncologist or close alone to consult the doctor.
Dr. Mukhtar also commended the efforts of the state through the presidential campaign to support 100 million women’s health as the countries work to provide the latest testing and diagnostic techniques to help in the early detection of the disease.
